BRPI0815540A8 - Novas formas de éster metílico de cddo - Google Patents

Novas formas de éster metílico de cddo

Info

Publication number
BRPI0815540A8
BRPI0815540A8 BRPI0815540A BRPI0815540A BRPI0815540A8 BR PI0815540 A8 BRPI0815540 A8 BR PI0815540A8 BR PI0815540 A BRPI0815540 A BR PI0815540A BR PI0815540 A BRPI0815540 A BR PI0815540A BR PI0815540 A8 BRPI0815540 A8 BR PI0815540A8
Authority
BR
Brazil
Prior art keywords
methyl ester
cddo methyl
new forms
cddo
usually
Prior art date
Application number
BRPI0815540A
Other languages
English (en)
Inventor
Walling John
D Parent Stephan
t jonaitis David
M Kral Robert
Original Assignee
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc, Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Inc
Publication of BRPI0815540A2 publication Critical patent/BRPI0815540A2/pt
Publication of BRPI0815540A8 publication Critical patent/BRPI0815540A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)

Abstract

NOVAS FORMAS DO ÉSTER METÍLICO DE CDDO. Composto triterpenoide, metil 2-ciano-3,12-dioxoleano-1,9 (11) -dien-28-oato (éster metílico de CDDO), com uma forma vítrea não cristalina e uma forma cristalina não hidratada que podem ser preparadas, por exemplo, a partir de uma solução saturada em metanol. A forma vítrea tem biodisponibilidade superior à da forma cristalina não hidratada. Cada forma do éster metílico de CDDO é um candidato de nível superior para uso, geralmente em dose sólida, no tratamento de uma série de estados patológicos, normalmente associados a processos inflamatórios.
BRPI0815540A 2007-08-15 2008-08-14 Novas formas de éster metílico de cddo BRPI0815540A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95593907P 2007-08-15 2007-08-15
PCT/US2008/009703 WO2009023232A1 (en) 2007-08-15 2008-08-14 Novel forms of cddo methyl ester

Publications (2)

Publication Number Publication Date
BRPI0815540A2 BRPI0815540A2 (pt) 2014-09-30
BRPI0815540A8 true BRPI0815540A8 (pt) 2023-04-11

Family

ID=40351005

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815540A BRPI0815540A8 (pt) 2007-08-15 2008-08-14 Novas formas de éster metílico de cddo

Country Status (28)

Country Link
US (3) US8088824B2 (pt)
EP (2) EP2450057B1 (pt)
JP (4) JP5005812B2 (pt)
KR (2) KR101481764B1 (pt)
CN (2) CN101820758B (pt)
AR (2) AR073155A1 (pt)
AT (1) ATE549035T1 (pt)
AU (1) AU2008287388B2 (pt)
BR (1) BRPI0815540A8 (pt)
CA (2) CA2871864C (pt)
CL (1) CL2008002417A1 (pt)
CY (2) CY1112864T1 (pt)
DK (2) DK2450057T3 (pt)
EA (2) EA018704B1 (pt)
ES (2) ES2382571T3 (pt)
HR (2) HRP20120350T1 (pt)
HU (1) HUE031866T2 (pt)
IL (2) IL203824A (pt)
LT (1) LT2450057T (pt)
MX (1) MX2010001628A (pt)
NZ (1) NZ583269A (pt)
PL (2) PL2187741T3 (pt)
PT (2) PT2187741E (pt)
SG (2) SG10201504650VA (pt)
SI (2) SI2187741T1 (pt)
TW (2) TWI486357B (pt)
WO (1) WO2009023232A1 (pt)
ZA (1) ZA201001066B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
BRPI0907423A2 (pt) * 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
SI2395979T1 (sl) * 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2536285T3 (en) 2010-02-18 2018-07-16 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
MX348862B (es) 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP2015527407A (ja) * 2012-09-10 2015-09-17 アッヴィ・インコーポレイテッド グリチルレチン酸誘導体およびその使用方法
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EP2739639A4 (en) 2012-09-28 2014-11-05 Applied Pharmaceutical Science Inc POLYMORPHES OF CDDO ETHYL SITES AND USES THEREOF
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) * 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
WO2014148455A1 (ja) 2013-03-19 2014-09-25 第一三共株式会社 テルペノイド誘導体
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
EP4736949A2 (en) 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
KR20170055482A (ko) 2014-09-10 2017-05-19 다이이찌 산쿄 가부시키가이샤 안질환 치료용 및 예방용 서방성 의약 조성물
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
KR102594322B1 (ko) 2014-12-19 2023-10-26 가이스틀리히 파마 아게 옥사티아진-유사 화합물의 제조방법
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
EP3256451B1 (en) 2015-02-12 2021-10-20 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
HUE062258T2 (hu) * 2015-07-02 2023-10-28 Acerta Pharma Bv (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
CN113164436A (zh) 2018-11-27 2021-07-23 协和麒麟株式会社 药物组合物
EP3999522B1 (en) 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
BR112022022599A2 (pt) 2020-05-09 2023-03-21 Reata Pharmaceuticals Holdings Llc Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317599C (en) * 1986-03-26 1993-05-11 Yukio Nezu 1,2,6-triphenyl-4(1h)-pyridinone derivatives, production and uses thereof
JPH01273020A (ja) * 1988-04-26 1989-10-31 Toray Ind Inc 有機非線形光学材料
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP2876144B2 (ja) * 1990-03-23 1999-03-31 東洋フアルマー株式会社 ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) * 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
JP2006515859A (ja) * 2002-05-13 2006-06-08 トラスティーズ オブ ダートマス カレッジ 阻害剤およびその使用法
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
WO2005057275A1 (ja) 2003-12-08 2005-06-23 Sony Corporation 液晶表示装置およびバックライト調整方法
US20060167097A1 (en) * 2004-04-16 2006-07-27 Cheppail Ramachandran Compositions and uses of Amooranin compounds
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Also Published As

Publication number Publication date
JP2012188438A (ja) 2012-10-04
HUE031866T2 (en) 2017-08-28
AR073155A1 (es) 2010-10-20
DK2187741T3 (da) 2012-04-16
EA201070149A1 (ru) 2010-08-30
TW200916476A (en) 2009-04-16
CN103254267B (zh) 2016-03-16
US8633243B2 (en) 2014-01-21
US20120330050A1 (en) 2012-12-27
EP2450057A1 (en) 2012-05-09
CA2696330C (en) 2015-03-24
TWI419899B (zh) 2013-12-21
JP5005812B2 (ja) 2012-08-22
DK2450057T3 (en) 2016-12-19
HK1143537A1 (en) 2011-01-07
SG177905A1 (en) 2012-02-28
CN103254267A (zh) 2013-08-21
KR20100056488A (ko) 2010-05-27
EP2187741A1 (en) 2010-05-26
IL203824A (en) 2017-04-30
HRP20120350T1 (hr) 2012-05-31
ZA201001066B (en) 2010-10-27
CN101820758B (zh) 2013-03-06
US8309601B2 (en) 2012-11-13
JP2018009001A (ja) 2018-01-18
SI2450057T1 (sl) 2017-01-31
JP2015164939A (ja) 2015-09-17
CY1112864T1 (el) 2016-04-13
LT2450057T (lt) 2016-12-27
CL2008002417A1 (es) 2009-03-27
EP2450057B1 (en) 2016-09-28
KR101481764B1 (ko) 2015-01-13
CA2871864A1 (en) 2009-02-19
IL251419A0 (en) 2017-05-29
CA2871864C (en) 2016-05-17
AR119704A2 (es) 2022-01-05
BRPI0815540A2 (pt) 2014-09-30
AU2008287388B2 (en) 2014-11-06
MX2010001628A (es) 2010-06-02
KR101544766B1 (ko) 2015-08-17
EA018704B1 (ru) 2013-10-30
EA201370109A1 (ru) 2014-01-30
KR20140024063A (ko) 2014-02-27
TW201402597A (zh) 2014-01-16
PL2450057T3 (pl) 2017-02-28
EP2187741B1 (en) 2012-03-14
ES2602978T3 (es) 2017-02-23
EA023550B1 (ru) 2016-06-30
CN101820758A (zh) 2010-09-01
ATE549035T1 (de) 2012-03-15
HRP20161503T1 (hr) 2017-01-13
CY1118329T1 (el) 2017-06-28
JP2010536754A (ja) 2010-12-02
US8088824B2 (en) 2012-01-03
US20090048204A1 (en) 2009-02-19
TWI486357B (zh) 2015-06-01
CA2696330A1 (en) 2009-02-19
ES2382571T3 (es) 2012-06-11
PT2450057T (pt) 2016-12-15
US20120071684A1 (en) 2012-03-22
EP2187741A4 (en) 2010-08-25
WO2009023232A1 (en) 2009-02-19
NZ583269A (en) 2012-03-30
SG10201504650VA (en) 2015-07-30
SI2187741T1 (sl) 2012-07-31
PT2187741E (pt) 2012-06-21
AU2008287388A1 (en) 2009-02-19
PL2187741T3 (pl) 2012-08-31

Similar Documents

Publication Publication Date Title
BRPI0815540A8 (pt) Novas formas de éster metílico de cddo
ECSP088774A (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2008003940A1 (es) Compuestos derivados de morfolino pirimidina sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer, enfermedades inflamatorias, enfermedades obstructivas de las vias aereas, enfermedades inmunes o enfermedades cardiovasculares.
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
MX358640B (es) Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
MY177567A (en) Azeotrope-like compositions comprising 1-chloro-3,3,3-trifluoropropene
MX2007009162A (es) Formas de dosis rsistente al alcohol.
NO20084779L (no) Behandling av idiopatisk pulmonell fibrose i tidlig stadium
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
SI3252069T1 (sl) (11beta,17beta)-17-hidroksi-11-(4-(metilsulfonil)fenil)-17- (pentalfluoro-metil)estra-4.9-dien-3-on za uporabo v zdravljenju bolezni
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2008000674A1 (es) Compuestos derivados de 1,4-diarilacetidinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como agente reductor de los niveles de colesterol, para el tratamiento de trastornos del metabolismo lipidico, aterosclerosis
CL2010001471A1 (es) Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR081514A1 (es) El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)